Kymera Therapeutics KYMR Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's other accrued liabilities?
- Kymera Therapeutics (KYMR) reported other accrued liabilities of $976K in Q1 2026.
- How has Kymera Therapeutics's other accrued liabilities changed year-over-year?
- Kymera Therapeutics's other accrued liabilities increased by 9.3% year-over-year, from $893K to $976K.
- What is the long-term trend for Kymera Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's other accrued liabilities has grown at a 18.0% compound annual growth rate (CAGR), from $106K to $242K.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.